In-vitro Thrombogenicity Assessment of Flow Diversion and Aneurysm Bridging Devices

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2015 May 16

PMID 25975924

Citations 33

Authors

Gaurav Girdhar

Junwei Li

Larisa Kostousov

John Wainwright

Wayne L Chandler

Affiliations

Soon will be listed here.

Abstract

Endoluminal devices such as metallic flow diversion (FD) and aneurysm bridging (AB) stents are used for treatment of intracranial aneurysms. Treatments are associated with thrombogenic events mandating the use of dual antiplatelet therapy in all cases. In the current in vitro study, we utilize a slow binding fluorogenic thrombin specific substrate to measure the thrombin generation potential of six devices: four FD devices (Pipeline™ Flex embolization device, Pipeline™ Flex embolization device with Shield Technology™, SILK+, FRED™) and two AB devices (Solitaire™ AB, LEO+). We show that the Pipeline™ Flex embolization device with Shield Technology™ has significantly lower peak thrombin and takes significantly longer time to achieve peak thrombin (time to peak) compared to the other three FD devices (p < 0.05), with statistically similar results to the less thrombogenic AB devices. We conclude that surface modification of endoluminal stents could be an effective method to mitigate thrombogenic complications.

Citing Articles

Immune Thrombocytopenic Purpura and Intracranial Stenting.

Pathan S J Pharm Pract. 2024; 37(5):1214-1219.

PMID: 38387095 PMC: 11378446. DOI: 10.1177/08971900241236121.

Delayed leukoencephalopathy following non-coil embolization flow diverter stent deployment for an intracranial aneurysm.

Muraoka S, Asai T, Hamasaki H, Fukui T, Suzuki N, Nishizawa T Neuroradiology. 2024; 66(3):427-429.

PMID: 38212489 DOI: 10.1007/s00234-024-03281-7.

Endovascular treatment of a wide-necked renal artery aneurysm with a flow diverter stent.

Porcaro P, Turchino D, Quarantelli M, Guercio L, Accarino G, Serra R Radiol Case Rep. 2023; 18(8):2854-2859.

PMID: 37388268 PMC: 10300470. DOI: 10.1016/j.radcr.2023.05.030.

Distal Flow Diversion with Anti-Thrombotically Coated and Bare Metal Low-Profile Flow Diverters-A Comparison.

Schungel M, Hoffmann K, Weber E, Maybaum J, Bailis N, Scheer M J Clin Med. 2023; 12(7).

PMID: 37048781 PMC: 10095446. DOI: 10.3390/jcm12072700.

Clinical outcomes of pipeline embolization devices with shield technology for treating intracranial aneurysms.

Luo C, Jin L, Dong J, Fu Z, Liu E, Yin S Front Neurol. 2022; 13:971664.

PMID: 36452166 PMC: 9702813. DOI: 10.3389/fneur.2022.971664.

References

Kuiper K, Robinson K, Chronos N, Cui J, Palmer S, Nordrehaug J . Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries. Scand Cardiovasc J. 1998; 32(5):261-8. DOI: 10.1080/14017439850139843. View

Chen C, Lumsden A, Ofenloch J, Noe B, Campbell E, Stratford P . Phosphorylcholine coating of ePTFE grafts reduces neointimal hyperplasia in canine model. Ann Vasc Surg. 1997; 11(1):74-9. DOI: 10.1007/s100169900013. View

Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T . High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost. 2008; 6(10):1720-5. DOI: 10.1111/j.1538-7836.2008.03117.x. View

Hemker H, Beguin S . Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost. 1995; 74(1):134-8. View

van Hylckama Vlieg A, Christiansen S, Luddington R, Cannegieter S, Rosendaal F, Baglin T . Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007; 138(6):769-74. DOI: 10.1111/j.1365-2141.2007.06738.x. View

Girdhar G, Read M, Sohn J, Shah C, Shrivastava S . In-vitro thrombogenicity assessment of polymer filament modified and native platinum embolic coils. J Neurol Sci. 2014; 339(1-2):97-101. DOI: 10.1016/j.jns.2014.01.030. View

Hemker H, Willems G, Beguin S . A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost. 1986; 56(1):9-17. View

Whelan D, van der Giessen W, Krabbendam S, van Vliet E, Verdouw P, Serruys P . Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart. 2000; 83(3):338-45. PMC: 1729350. DOI: 10.1136/heart.83.3.338. View

Murayama Y, Nien Y, Duckwiler G, Gobin Y, Jahan R, Frazee J . Guglielmi detachable coil embolization of cerebral aneurysms: 11 years' experience. J Neurosurg. 2003; 98(5):959-66. DOI: 10.3171/jns.2003.98.5.0959. View

10.

Young G, Sorensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key N . Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013; 121(11):1944-50. PMC: 3645054. DOI: 10.1182/blood-2012-08-378935. View

11.

Lewis A, Stratford P . Phosphorylcholine-coated stents. J Long Term Eff Med Implants. 2003; 12(4):231-50. View

12.

Nelson P, Lylyk P, Szikora I, Wetzel S, Wanke I, Fiorella D . The pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol. 2010; 32(1):34-40. PMC: 7964968. DOI: 10.3174/ajnr.A2421. View

13.

Heller R, Dandamudi V, Lanfranchi M, Malek A . Effect of antiplatelet therapy on thromboembolism after flow diversion with the pipeline embolization device. J Neurosurg. 2013; 119(6):1603-10. DOI: 10.3171/2013.7.JNS122178. View

14.

Jeong H, Seo J, Kim S, Jung C, Suh S . Clinical practice guideline for the management of intracranial aneurysms. Neurointervention. 2014; 9(2):63-71. PMC: 4239410. DOI: 10.5469/neuroint.2014.9.2.63. View

15.

Chandler W, Roshal M . Optimization of plasma fluorogenic thrombin-generation assays. Am J Clin Pathol. 2009; 132(2):169-79. DOI: 10.1309/AJCP6AY4HTRAAJFQ. View

16.

Shapiro M, Becske T, Sahlein D, Babb J, Nelson P . Stent-supported aneurysm coiling: a literature survey of treatment and follow-up. AJNR Am J Neuroradiol. 2011; 33(1):159-63. PMC: 7966171. DOI: 10.3174/ajnr.A2719. View

17.

Alderazi Y, Shastri D, Kass-Hout T, Prestigiacomo C, Gandhi C . Flow diverters for intracranial aneurysms. Stroke Res Treat. 2014; 2014:415653. PMC: 4054970. DOI: 10.1155/2014/415653. View

18.

Delgado Almandoz J, Crandall B, Scholz J, Fease J, Anderson R, Kadkhodayan Y . Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the pipeline embolization device. AJNR Am J Neuroradiol. 2013; 35(1):128-35. PMC: 7966488. DOI: 10.3174/ajnr.A3621. View

19.

Hemker H, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R . Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33(1):4-15. DOI: 10.1159/000071636. View

20.

Kallmes D, Hanel R, Lopes D, Boccardi E, Bonafe A, Cekirge S . International retrospective study of the pipeline embolization device: a multicenter aneurysm treatment study. AJNR Am J Neuroradiol. 2014; 36(1):108-15. PMC: 7965920. DOI: 10.3174/ajnr.A4111. View